Merck Reports the Initiation of a Series of P-III Trials for Bomedemstat, Nemtabrutinib, MK-2870 and MK-5684 to Treat Solid Tumors
Shots:
- Merck initiated 7 P-III trials for the evaluation of Bomedemstat, Nemtabrutinib, MK-2870 & MK-5684 to treat solid tumors
- The company initiated (MK-3543-006) trial for Bomedemstat in ET patients with DCHR rate as 1EP & DOCHR, DOHR & EFS as 2EPs & (BELLWAVE-011) for Nemtabrutinib in CLL & SLL patients (n=1,200) with ORR & PFS as 1EPs & OS & DoR per iwCLL Criteria 2018 as 2EPs
- Merck initiated 3 trials for MK-2870 incl. (MK-2870-004), (MK-2870-007) & (MK-2870-005) in NSCLC patients (n=556, 614 & 710) with 1EPs of (PFS & OS), (OS) & (PFS) & 2EPs of (ORR & DoR), (PFS, DoR & OR) & (ORR & DoR). For MK-5684, (OMAHA1) & (OMAHA2a) trials in mCRPC patients (1,200 & 1,500) with 1EPs of (rPFS) & (OS & rPFS) & 2EPs of TFST, ORR & DoR for both trials
Ref: Merck | Image: Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
